ProCE Banner Activity

Phase III LUNAR: Tumor Treating Fields + Standard Second-line Therapy in Metastatic NSCLC With Progression On/After Platinum-Based Therapy

Conference Coverage
Slideset

LUNAR met its primary endpoint, demonstrating a statistically significant OS benefit when TTFields was added to standard docetaxel or immune checkpoint inhibitor therapy in patients with metastatic NSCLC previously treated with platinum-based therapy.

Released: June 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure